New immunotherapy combo aims to extend life in Tough-to-Treat colorectal cancer

NCT ID NCT07152821

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 8 times

Summary

This Phase 3 trial is testing whether a combination of two immunotherapy drugs, botensilimab and balstilimab, can help people with advanced colorectal cancer that can't be removed by surgery and has stopped responding to chemotherapy. About 834 participants will receive either the drug combo or best supportive care. The main goal is to see if the drugs help people live longer, with additional focus on tumor shrinkage, quality of life, and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
botensilimab and balstilimab (immunotherapy drugs)
What this could lead to
If it works, this could offer a new treatment option for people with advanced colorectal cancer who have run out of standard therapies, potentially helping them live longer and have a better quality of life.
What could go wrong
This is a large Phase 3 trial, but immunotherapy doesn't work for everyone and can cause serious side effects. The cancer type studied (non-MSI-H) is typically less responsive to immunotherapy, so benefits may be modest or not seen at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kingston Health Science Centre

    Kingston, Ontario, K0H1H0, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.